Nearly 20 expensive medications will escape Medicare price negotiations under the 2025 budget law, costing patients and ...

Pfizer CEO Albert Bourla says RFK Jr.'s appointment was not up to him, but he has found common ground with the vaccine ...

Premiums and prescription prices are rising for North Carolina Medicare enrollees in 2026 as plan choices narrow and benefits ...

Learn about the benefits that become permanent features of Medicare in 2026 and how they have been changed or updated since ...

A significant percentage of the S&P 500's return over the past few decades is based on dividends reinvested and the power of ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...

A supply fee for drugs subject to Medicare Part D price negotiations is being touted as “essential” to the sustainability of long-term care pharmacies that serve assisted living communities and ...

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to ...

Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...